Dr. Katherine Van Loon on Recognizing Recurrences in Gastrointestinal Cancers

Oral selinexor as maintenance therapy extended progression-free survival in patients with TP53 wild-type advanced or recurrent endometrial cancer.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with platinum-doublet chemotherapy.